Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68


MOZ-TIF2 inhibits transcription by nuclear receptors and p53 by impairment of CBP function.

Kindle KB, Troke PJ, Collins HM, Matsuda S, Bossi D, Bellodi C, Kalkhoven E, Salomoni P, Pelicci PG, Minucci S, Heery DM.

Mol Cell Biol. 2005 Feb;25(3):988-1002.


MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP.

Deguchi K, Ayton PM, Carapeti M, Kutok JL, Snyder CS, Williams IR, Cross NC, Glass CK, Cleary ML, Gilliland DG.

Cancer Cell. 2003 Mar;3(3):259-71.


MOZ-TIF2 alters cofactor recruitment and histone modification at the RARbeta2 promoter: differential effects of MOZ fusion proteins on CBP- and MOZ-dependent activators.

Collins HM, Kindle KB, Matsuda S, Ryan C, Troke PJ, Kalkhoven E, Heery DM.

J Biol Chem. 2006 Jun 23;281(25):17124-33. Epub 2006 Apr 13.


A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia.

Carapeti M, Aguiar RC, Goldman JM, Cross NC.

Blood. 1998 May 1;91(9):3127-33.


Acute mixed lineage leukemia with an inv(8)(p11q13) resulting in fusion of the genes for MOZ and TIF2.

Liang J, Prouty L, Williams BJ, Dayton MA, Blanchard KL.

Blood. 1998 Sep 15;92(6):2118-22.


MOZ fusion proteins in acute myeloid leukaemia.

Troke PJ, Kindle KB, Collins HM, Heery DM.

Biochem Soc Symp. 2006;(73):23-39. Review.


Bromodomain-PHD finger protein 1 is critical for leukemogenesis associated with MOZ-TIF2 fusion.

Shima H, Yamagata K, Aikawa Y, Shino M, Koseki H, Shimada H, Kitabayashi I.

Int J Hematol. 2014 Jan;99(1):21-31. doi: 10.1007/s12185-013-1466-x. Epub 2013 Nov 21.


PU.1-mediated upregulation of CSF1R is crucial for leukemia stem cell potential induced by MOZ-TIF2.

Aikawa Y, Katsumoto T, Zhang P, Shima H, Shino M, Terui K, Ito E, Ohno H, Stanley ER, Singh H, Tenen DG, Kitabayashi I.

Nat Med. 2010 May;16(5):580-5, 1p following 585. doi: 10.1038/nm.2122. Epub 2010 Apr 25.


Activation of AML1-mediated transcription by MOZ and inhibition by the MOZ-CBP fusion protein.

Kitabayashi I, Aikawa Y, Nguyen LA, Yokoyama A, Ohki M.

EMBO J. 2001 Dec 17;20(24):7184-96.


MOZ increases p53 acetylation and premature senescence through its complex formation with PML.

Rokudai S, Laptenko O, Arnal SM, Taya Y, Kitabayashi I, Prives C.

Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3895-900. doi: 10.1073/pnas.1300490110. Epub 2013 Feb 19.


Expression of the MOZ-TIF2 oncoprotein in mice represses senescence.

Largeot A, Perez-Campo FM, Marinopoulou E, Lie-a-Ling M, Kouskoff V, Lacaud G.

Exp Hematol. 2016 Apr;44(4):231-7.e4. doi: 10.1016/j.exphem.2015.12.006. Epub 2016 Feb 5.


The monocytic leukemia zinc finger protein MOZ is a histone acetyltransferase.

Champagne N, Pelletier N, Yang XJ.

Oncogene. 2001 Jan 18;20(3):404-9.


Functional interplay between CBP and PCAF in acetylation and regulation of transcription factor KLF13 activity.

Song CZ, Keller K, Chen Y, Stamatoyannopoulos G.

J Mol Biol. 2003 May 30;329(2):207-15.


Molecular architecture of quartet MOZ/MORF histone acetyltransferase complexes.

Ullah M, Pelletier N, Xiao L, Zhao SP, Wang K, Degerny C, Tahmasebi S, Cayrou C, Doyon Y, Goh SL, Champagne N, Côté J, Yang XJ.

Mol Cell Biol. 2008 Nov;28(22):6828-43. doi: 10.1128/MCB.01297-08. Epub 2008 Sep 15. Erratum in: Mol Cell Biol. 2009 Feb;29(3):942.


RT-PCR analysis of the MOZ-CBP and CBP-MOZ chimeric transcripts in acute myeloid leukemias with t(8;16)(p11;p13).

Panagopoulos I, Isaksson M, Lindvall C, Björkholm M, Ahlgren T, Fioretos T, Heim S, Mitelman F, Johansson B.

Genes Chromosomes Cancer. 2000 Aug;28(4):415-24.


[FGFR1 and MOZ, two key genes involved in malignant hemopathies linked to rearrangements within the chromosomal region 8p11-12].

Pébusque MJ, Chaffanet M, Popovici C, Birnbaum D.

Bull Cancer. 2000 Dec;87(12):887-94. Review. French.


Detection of CBP rearrangements in acute myelogenous leukemia with t(8;16).

Giles RH, Dauwerse JG, Higgins C, Petrij F, Wessels JW, Beverstock GC, Döhner H, Jotterand-Bellomo M, Falkenburg JH, Slater RM, van Ommen GJ, Hagemeijer A, van der Reijden BA, Breuning MH.

Leukemia. 1997 Dec;11(12):2087-96.


Supplemental Content

Support Center